Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > Oh my. We seem to have a pattern here.

<< Previous

Bullboard Posts

Next >>

Comment by Amazighon Oct 08, 2021 8:32am

109 Views

Post# 33987715

RE:Oh my. We seem to have a pattern here.

I advise you to buy some shares, while they're so cheap. Meanwhile you still can bash this stock, because you have to pay bills and s h i t. No one will know you bought some, including your boss. You'll thank me in couple of months. ;-) Cheers, Amazigh

<< Previous

Bullboard Posts

Next >>

Cannara reports record growth and profitability in Q4 2023